Mordechai R. Kramer, MD; Sara E. Marshall, MBBCh; David W. Denning, MBBS; Anne M. Keogh, MBBS; Richard M. Tucker, MD; John N. Galgiani, MD; Norman J. Lewiston, MD; David A. Stevens, MD; James Theodore, MD
Itraconazole is a new triazole antifungal (1-3). The infrequency of serious toxicity makes it particularly appropriate in patients receiving cyclosporine therapy, in whom nephrotoxicity is common. A related drug, ketoconazole, interacts significantly with cyclosporine (4). However, no interaction has been clearly documented between itraconazole and cyclosporine. We recently treated seven patients with itraconazole for serious fungal infections after heart-lung, heart, or lung transplantation. We observed an interaction between itraconazole and cyclosporine with subsequent impairment of patient renal function.
Four heart-lung, two heart, and one lung transplant recipients were treated with itraconazole (Janssen Pharmaceutica, Beerse, Belgium) for aspergillosis (five
Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, et al. Cyclosporine and Itraconazole Interaction in Heart and Lung Transplant Recipients. Ann Intern Med. ;113:327–329. doi: 10.7326/0003-4819-113-4-327
Download citation file:
Published: Ann Intern Med. 1990;113(4):327-329.
Cardiology, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use